You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
pegaspargase
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
vinCRIStine,
procarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cyclophosphamide,
DOXOrubicin,
vinCRIStine,
dexamethasone,
pegaspargase
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (PDRP prior authorization),
etoposide,
ifosfamide,
mesna,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022

Pages